Thromboembolism associated with the new contraceptive Yasmin.
van Grootheest
Kees
K
Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH 's-Hertogenbosch, Netherlands. ac.vangrootheest@lareb.nl
Vrieling
Tom
T
D000293:Adolescent; D000328:Adult; D000736:Androstenes / Q000009:adverse effects*; D003277:Contraceptives, Oral, Combined / Q000009:adverse effects*; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D008875:Middle Aged; D000451:Mineralocorticoid Receptor Antagonists / Q000009:adverse effects*; D011655:Pulmonary Embolism / Q000139:chemically induced; D013923:Thromboembolism / Q000139:chemically induced*; D020246:Venous Thrombosis / Q000139:chemically induced
D000736:Androstenes; D003277:Contraceptives, Oral, Combined; D000451:Mineralocorticoid Receptor Antagonists; C035144:drospirenone